5-Methyl-6-phenyl-1,3,5,6-tetrahydro-3,6-methano-l,5-benzodiazocine-2,4-dione (BA 41899): Representative of a Novel Class of Purely Calcium-Sensitizing Agents

Journal of Medicinal Chemistry

Volumn 38, Issue 15, 1995, Pages 2946-2954

  Herold, Peter ^a   Herzig, Joachim W ^a   Wenk, Paul ^a   Leutert, Thomas ^a   Zbinden, Paul ^a   Fuhrer, Walter ^a   Stutz, Stefan ^a   Schenker, Karl ^a   Meier, Max ^a   Rihs, Greti ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1,3,5,6 TETRAHYDRO 5 METHYL 6 PHENYL 3,6 METHANO 1,5 BENZODIAZOCINE 2,4 DIONE; AZOCINE DERIVATIVE; BA 41899; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CHRONOTROPISM; CONGESTIVE HEART FAILURE; DRUG ACTIVITY; DRUG EFFECT; DRUG STRUCTURE; ENANTIOMER; HEART MUSCLE CELL; INOTROPISM; NONHUMAN; SKINNED MUSCLE FIBER; SWINE;

ANIMAL; AZOCINES; CALCIUM; CARDIOTONIC AGENTS; COMPARATIVE STUDY; ELECTRIC STIMULATION; GUINEA PIGS; HEART ATRIUM; HEART FAILURE, CONGESTIVE; IMIDAZOLES; IN VITRO; ISOMETRIC CONTRACTION; MYOCARDIAL CONTRACTION; MYOCARDIUM; PHOSPHODIESTERASE INHIBITORS; SENSITIVITY AND SPECIFICITY; STEREOISOMERISM; SWINE;

EID: 0029101546     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm00015a017     Document Type: Article

References (38)

1. Smith, W. M. Epidemiology of congestive heart failure. Am. J. Cardiol. 1985, 55, 3A-8A.
2. Kannel, W. B.; Cupples, A. Epidemiology and risk profile of cardiac failure. Cardiovasc. Drug Ther. 1988, 2, 387-395.
3. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N. Engl. J. Med. 1987, 316, 1429-1435.
4. Kannel, W. B.; Belanger, A. J. Epidemiology of heart failure. Am. Heart J. 1991, 121 (3 Part 1), 951-957.
5. Gillum, R. F. Heart failure in the United States 1970-1985. Am. Heart J. 1987, 121 (4), 1043-1045.
6. Katz, A. M. Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Circulation 1986, 73 (Suppl. 3), 85-89.
7. Hasenfuss, G.; Holubarsch, C.; Just, H.; Blanchard, E.; Mulieri, L. A.; Alpert, N. R. Energetic aspects of inotropic interventions in rat myocardium. Basic Res. Cardiol. 1987, 82 (Suppl. 2), 251-259.
8. max) in isolated contractile structures from mammalian heart muscle. Arzneim.-Forsch. 1981, 31, 188-191.
9. 2+ binding and ATPase activity of dog cardiac myofibrils by AR-L 115BS, a novel cardiotonic agent. Circ. Res. 1982, 51, 290-294.
10. Lues, I.; Siegel, R.; Harting, J. Effect of isomazole on the responsiveness to calcium of the contractile elements in skinned cardiac muscle fibres of various species. Eur. J. Pharmacol. 1988, 46, 145-153.
11. Van Meel, J. C. A. Effects of some cardiotonic agents on contractility of skinned fibres from mammalian heart. Arzneim.- Forsch. 1987, 37, 679-682.
12. Miiller-Beckmann, B.; Freund, P.; Honeijager, P.; Kling, L.; Riiegg, J. C. In vitro investigations on a new positibve inotropic and vasodilating agent (BM 14, 478), that increases myocardial cyclic AMP content and myofibrillar calcium sensitivity. J. Cardiovasc. Pharmacol. 1988, 11, 8-16.
13. 2+ sensitization by the cardiotonic agent APP 201-533. Basic Res. Cardiol. 1989, 84 (Suppl 1), 117-124.
14. Herzig, J. W.; Quast, U. Increase in calcium sensitivity of myocardial contractile structures by DPI-201-106. J. Mol. Cell Cardiol. 1984, 16 (Suppl 3), 6.
15. Allen, D. G.; Lee, J. A. EMD 53998 increases tension with little effect on the amplitude of calcium transients in isolated ferret ventricular muscle. J. Physiol. (London) 1989, 416, 43P.
16. Ferroni, C.; Spurgeon, H. A.; Klockow, M.; Lakatta, E. G.; Capogrossi, M. C. Contractile potentiation without increasing cytosolic calcium in single rat ventricular myocytes. FASEB J. 1989, 3, A1039.
17. Jonas, R. D.; Piulats, J.; Lues, I.; Klockow, M. European Patent Appl. 294, 647, 1988.
18. Jonas, R. D.; Lues, I. D.; Minck, K. D.; Klockow, M. D. European Patent Appl. 579, 077, 1993.
19. Walker, G. N.; Schenker, K. Methano-benzazepinium compounds. U. S. Patent 3, 291, 806, 1966.
20. Baumgarten, H. E.; Staklis, A. Reaction of amines. XIV. An oxidative rearrangement of amides. J. Am. Chem. Soc. 1965, 87, 1141-1142.
21. Walker, G. N. 1, 4-Dihydro-1, 4-ethano-isoquinolines. U. S. Patent 3, 379, 731, 1966.
22. Takayuki, S.; Kumihiro, N.; Shunichi, Y. Diphenylphosphoryl azide. A new convenient reagent for a modified Curtius reaction and for the peptide synthesis. J. Am. Chem. Soc. 1972, 94, 6203-6205.
23. Krow, G. R. Nitrogen insertion reactions of bridged bicyclic ketones. Regioselective lactam formation. Tetrahedron 1981, 37, 1283-1307.
24. Schenker, K. 2, 3, 4, 5-Tetrahydro-1, 4-methano-lH-3-benzazepines. Neth. Appl. 6, 607, 339, 1965.
25. Gawly, R. E. The Beckmann reactions: Rearrangements, elimination-additions, fragmentations, and rearrangement-cyclizations. Org. React. (N Y.) 1988, 35, 1.
26. Enders, D. Asymmetric synthesis using the SAMP-/RAMP- hydrazone method: (S)-(+)-4-Methyl-3-heptanone. Org. Synth. 1987, 65, 183-202.
27. Herzig, J. W.; Leijendekker, W. J. Myocardial Ca sensitivity and energy turnover as modulated by inorganic phosphate and EMD 53998, a novel inotropic agent. In New Aspects in Treatment of Failing Heart; Yasuda, H., Morgan, H. E., Eds.; Springer: Tokyo, 1992; pp 128-132.
28. Beier, N.; Harting, J.; Jonas, R.; Klockow, M.; Lues, I.; Haeusler, G. The novel cardiotonic agent EMD 53998 is a potent “calcium sensitizer”. J. Cardiovasc. Pharmacol. 1991, 18, 17-27.
29. 2+ sensitization and phosphodiesterase III inhibitory effects in guinea pig myocardium. Circ. Res. 1992, 70, 1081-1090.
30. Solaro, R. J.; Gambassi, G.; Warshaw, D. M.; Keller, M. R.; Spurgeon, H. A.; Beier, N.; Lakatta, E. G. Stereoselective actions of thiadiazinones on canine cardiac myocytes and myofilaments. Circ. Res. 1993, 73, 981-990.
31. 2+ on cross-bridge turnover kinetics in skinned single rabbit psoas fibers: implications for regulation of muscle contraction. Proc. Natl. Acad. Sci. U. S A. 1988, 85, 3265-3269.
32. Herzig, J. W.; Riiegg, J. C.; Solaro, R. J. Myocardial excitation- contraction coupling as influenced through modulation of the calcium sensitivity of the contractile proteins. Heart Failure 1991, January, 244-250.
33. 2+- sensitizing agent. Pfliiger’s Arch. Eur. J. Physiol. 1992, 421, 388-390.
34. Zimmermann, N.; Boknik, P.; Gams, E.; Herzig, J. W.; Neumann, J.; Schmitz, W.; Scholz, H.; Wenzlaff, H. Positive inotropic effects of the calcium sensitizer CGP 48506 in guinea pig myocardium. Manuscript in preparation.
35. Perrin, D. D.; Sayce, I. G. Computer calculation of equilibrium concentrations in mixtures of metal ions and complexing species. Talanta 1967, 14, 833-842.
36. Fabiato, A. Myoplasmic free calcium concentration reached during the twitch of an intact isolated cardiac cell and during calcium-induced release of calcium from the sarcoplasmic reticulum of a skinned cardiac cell from the adult rat or rabbit ventricle. J. Gen. Physiol. 1981, 78, 457-497.
37. Marki, F.; Bttch, O.; Delina-Stala, A.; Kraetz, J.; Petermann, H.; Radeke, E.; Schweizer, A.; Thomann, P.; Truog, A. Sulfonyliminoimidazolidines, a new class of oral hypoglycemic agents. 4. Toxicity and general pharmacology of l-(p-(2-(crotonylamino)- ethyl)-phenylsulfonyl)-3-cyclohexyl-2-iminoimidazolidine (CGP 11112). Arzneim.-Forsch. 1984, 34, 247-250.
38. Sheldrick, G. M. SHELXS-86. In Crystallographic Computing 3; Sheldrick, G. M., Kruger, C., Goddard, R., Eds.; Oxford University Press: Oxford, U. K., 1985; pp 175-189.